Trial Profile

Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belatacept (Primary) ; Methylprednisolone; Mycophenolate mofetil; Mycophenolic acid; Tacrolimus
Indications Renal transplant rejection
Focus Adverse reactions

08 Jun 2022 Primary endpoint has not been met. (change in eGFR at 2 years post-transplant in Tac+MPA), as per Results presented at the 2022 American Transplant Congress
08 Jun 2022 Results presented at the 2022 American Transplant Congress
08 Dec 2020 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com